SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets close in 4 hrs 41 mins

Sanofi (SNY)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
45.24-0.11 (-0.25%)
As of 11:19AM EDT. Market open.
People also watch
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close45.35
Open45.24
Bid0.00 x
Ask0.00 x
Day's Range45.22 - 45.43
52 Week Range36.81 - 45.95
Volume568,597
Avg. Volume1,736,660
Market Cap111.8B
Beta0.76
PE Ratio (TTM)23.38
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.48%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod
    Zacks58 minutes ago

    Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

    Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

  • Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
    Zacks3 hours ago

    Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study

    Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.

  • Reuters4 hours ago

    Sanofi hires advisors for European generic drugs unit sale -sources

    FRANKFURT/LONDON, March 29 (Reuters) - French drug maker Sanofi has hired advisers for the sale of its European generic drug business, several sources familiar with matter told Reuters, ahead of an auction process which is expected to start after the European summer. Rothschild, JP Morgan and Morgan Stanley have been asked to organise the long-awaited deal which could be worth more than 2 billion euros ($2.2 billion), the sources said. Bankers have been vying for a mandate for the past 18 months since Sanofi boss Olivier Brandicourt took charge of the French firm and decided to put the business under review.